Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Delayed Hemolytic Anemia after Treatment with Artesunate: Case Report and Literature Review

Author(s): Mohammadreza Salehi, Hosein Masoumi-Asl, Mehrdad Assarian, Niloofar Khoshnam-Rad, Afsaneh Motevalli Haghi, Mehran Nikbakht and Hossein Khalili*

Volume 14, Issue 1, 2019

Page: [60 - 66] Pages: 7

DOI: 10.2174/1574886313666181109150157

Price: $65

Abstract

Background: In recent years, few cases of post-artemisinin delayed hemolysis have been reported.

Objective: All cases of post-artemisinin delayed hemolysis were reported from non-middle east areas. No case of post-artemisinin delayed hemolysis has yet been reported from this region. In this paper, we describe a case of post-artemisinin delayed hemolysis in an Iranian female. Moreover, previous reports have been reviewed.

Methods: Patient’s data including demographic characteristics, past medical, drug and travelling history, present illness, vital signs, laboratory data, clinical course of current illness and follow-up findings were considered.

Results: A 27-year-old female with a recent travel history to Ghana admitted with severe falciparum malaria. She was successfully treated with parenteral artesunate. However after 12 days of post artesunate treatment, she returned with dark urine, malaise and fatigue.

Conclusion: Considering the clinical course and base on a reliable causality assessment scale, post artesunate delay hemolytic anemia was possible.

Keywords: Artesunate, Falciparum malaria, delayed hemolysis, PADH, lactate dehydrogenase, GMP.

« Previous Next »
Graphical Abstract

[1]
World Health Organization. Guidelines for treatment of malaria. Available from: http://apps.who.int/iris/bitstream/handle/10665/ 162441/9789241549127_eng.pdf;jsessionid=E259DE26F76EA8112EEA7CBFB72E3DF8?sequence=1 Accessed date 22 July 2018.
[2]
Saker L, Lee K, Cannito B, Gilmore A, Campbell-Lendrum D. Globalization and infectious diseases : A review of the linkages. Trop Med 2004; 3: 63.
[3]
Price R, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60(4): 547-55.
[4]
Rehman K, Lötsch F, Kremsner PG, Ramharter M. Haemolysis associated with the treatment of malaria with artemisinin derivatives: A systematic review of current evidence. Int J Infect Dis 2014; 29: e268-73.
[5]
Gómez-Junyent J, Ruiz-Panales P, Calvo-Cano A, Gascón J, Muñoz J. Delayed haemolysis after artesunate therapy in a cohort of patients with severe imported malaria due to Plasmodium falciparum. Enferm Infecc Microbiol Clin 2017; 35(8): 516-9.
[6]
Report MW. Morbidity and Mortality Weekly Report (MMWR) Update on cases of delayed hemolysis after parenteral artesunate therapy for malaria - United States, 2008 and 2013. MMWR Morb Mortal Wkly Rep 2014; 63(34): 753-5.
[7]
Arguin PM. Case definition: Postartemisinin delayed hemolysis A microRNA involved in the germinal center reaction. Blood 2014; 124(2): 157-9.
[8]
Rolling T, Agbenyega T, Krishna S, Kremsner PG, Cramer JP. Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective. Travel Med Infect Dis 2015; 13(2): 143-9.
[9]
Centers for Disease Control and Prevention (CDC). Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria--worldwide, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 62(1): 5-8.
[10]
Medicines for Malaria Venture. Experts Group Meeting on delayed haemolytic anaemia following treatment with injectable artesunate 2013. Available from: https://www.mmv.org/sites/ default/files/uploads/docs/events/2013/InjectableArtesunateExpertGroupMeeting.pdf
[11]
Kurth F, Lingscheid T, Steiner F, et al. Hemolysis after oral artemisinin combination therapy for uncomplicated Plasmodium falciparum Malaria. Emerg Infect Dis 2016; 22(8): 1381-6.
[12]
Rolling T, Agbenyega T, Issifou S, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria - A double-center prospective study. J Infect Dis 2014; 209(12): 1921-8.
[13]
Tsuchido Y, Nakamura-Uchiyama F, Toyoda K, et al. Development of delayed hemolytic anemia after treatment with oral Artemether–Lumefantrine in two patients with severe falciparum malaria. Am J Trop Med Hyg 2017; 96(5): 1185-9.
[14]
Garratty G, Petz LD. Drug-induced immune hemolytic anemia. Am J Med 1975; 58(3): 398-407.
[15]
Burri C, Ferrari G, Ntuku HM, et al. Short report: Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: A manageable issue. Am J Trop Med Hyg 2014; 91(4): 821-3.
[16]
Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J 2012; 11: 102.
[17]
Norouzinejad F, Ghaffari F, Raeisi A, Norouzinejad A. Epidemiological status of malaria in Iran, 2011-2014. Asian Pac J Trop Med 2016; 9(11): 1055-61.
[18]
Plewes K, Haider MS, Kingston HW, et al. Severe falciparum malaria treated with artesunate complicated by delayed onset haemolysis and acute kidney injury. Malar J 2015; 14: 246.
[19]
Lee J, Krajden S, Graham C, Pavenski K, Keystone JS, Kain KC. Severe delayed hemolysis associated with regulated parenteral antimalarial drug. Emerg Infect Dis 2015; 21(1): 164-6.
[20]
Charles M, Patterson JM, Asadi L, Houston S. Case report: Delayed hemolysis after parenteral artesunate therapy for severe malaria in two returning Canadian travelers. Am J Trop Med Hyg 2015; 93(4): 819-21.
[21]
Aldámiz-Echevarría Lois T, López-Polín A, Norman FF, Monge-Maillo B, López-Vélez R, Perez-Molina JA. Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infections in Spain. Travel Med Infect Dis 2017; 15: 52-6.
[22]
Corpolongo A, De Nardo P, Ghirga P, et al. Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine. Malar J 2012; 11: 91.
[23]
De Nardo P, Oliva A, Giancola ML, et al. Haemolytic anaemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria. Infection 2013; 41(4): 863-5.
[24]
Raffray L, Receveur M-C, Beguet M, Lauroua P, Pistone T, Malvy D. Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: A case report. Malar J 2014; 13: 398.
[25]
Kobayashi T, Hayakawa K, Kato YA. 41-year-old man with fever and dark-coloured urine. J Travel Med 2016; 23(3): 1-2.
[26]
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[27]
Pallasch TJ. Principles of pharmacoterapy: IV. Hematologic drug reactions. Anesth Prog 1989; 36(1): 1-4.
[28]
Jarvis JN, Coltart CE, Pule M, Chiodini PL, Doherty T. Artemisinin therapy and severe delayed haemolysis. Lancet 2013; 382(9887): 180.
[29]
Zoller T, Junghanss T, Kapaun A, Gjørup I, et al. Intravenous artesunate for severe malaria in travelers, europe. Emerg Infect Dis 2011; 17(5): 771-7.
[30]
Caramello P, Balbiano R. De blasi T, Chiriotto M, Deagostini M, Calleri G. Severe malaria, artesunate and haemolysis. J Antimicrob Chemother 2012; 67(8): 2053-4.
[31]
Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard G-D, Cramer JP. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: Case report of three patients with hyperparasitaemia. Malar J 2012; 11: 169.
[32]
Kano S. Artemisinin-based combination therapies and their introduction in Japan. J Infect Chemother 2010; 16(6): 375-82.
[33]
Laura R, Philippe L, Marie-Pierre H. A case of hemolytic anemia after severe malaria successfully treated with artesunate 2012. Available from:.http://hdl.handle.net/2268/162066
[34]
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49(9): 2229-32.
[35]
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538.

Rights & Permissions Print Cite
Article Metrics
33
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy